These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1752391)

  • 1. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
    Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
    Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
    Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
    J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B.
    Shindo M; Okuno T; Arai K; Matsumoto M; Takeda M; Takino T; Sokawa Y
    Hepatology; 1989 May; 9(5):715-9. PubMed ID: 2468593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
    Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
    J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
    Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
    Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapeutic efficacy of interferon for patients with chronic hepatitis C.
    Takeda T; Kuroki T; Fukuda K; Yabusako T; Nishiguchi S; Nakajima S; Shiomi S; Seki S; Monna T; Sakurai M
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():104-8. PubMed ID: 8359619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis.
    Kakumu S; Arao M; Yoshioka K; Ichimiya H; Murase K; Aoi T; Kusakabe A
    Am J Gastroenterol; 1989 Jan; 84(1):40-5. PubMed ID: 2521421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
    Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
    Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
    Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
    J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
    Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
    J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
    Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
    Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E; Mizokami M; Suzuki K; Ohba KI; Ohno T; Mizuno M; Iijima Y; Saito H; Nemoto A; Nukuta N
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.
    Kakumu S; Yoshika K; Tanaka K; Higashi Y; Kurokawa S; Hirofuji H; Kusakabe A
    J Med Virol; 1993 Sep; 41(1):65-70. PubMed ID: 8228941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis.
    Saito T; Shinzawa H; Kuboki M; Ishibashi M; Toda H; Okuyama Y; Nakamura T; Yamada N; Wakabayashi H; Togashi H
    Am J Gastroenterol; 1994 May; 89(5):681-6. PubMed ID: 8172137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage.
    Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
    Gastroenterol Jpn; 1991 Apr; 26(2):162-9. PubMed ID: 1710193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis.
    Nakano Y; Kiyosawa K; Sodeyama T; Tanaka E
    Am J Gastroenterol; 1990 Jan; 85(1):24-9. PubMed ID: 1688684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.
    Pawlotsky JM; Hovanessian AG; Roudot-Thoraval F; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
    Antimicrob Agents Chemother; 1996 Feb; 40(2):320-4. PubMed ID: 8834873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells.
    Grandér D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Björklund AC; Befrits R; Björkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
    Scand J Gastroenterol; 1996 Jun; 31(6):604-11. PubMed ID: 8789901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.